No abstract

Although much progress has been made in the treatment of gliomas, the prognosis for patients with gliomas is still very poor. Stem cell-based therapies may be promising options for glioma treatment. Recently, many studies have reported that umbilical cord-derived mesenchymal stromal/stem cells (UC-MSCs) are ideal gene vehicles for tumor gene therapy. Interleukin 24 (IL-24) is a pleiotropic immunoregulatory cytokine that has an apoptotic effect on many kinds of tumor cells and can inhibit the growth of tumors specifically without damaging normal cells. In this study, we investigated UC-MSCs as a vehicle for the targeted delivery of IL-24 to tumor sites. UC-MSCs were transduced with lentiviral vectors carrying green fluorescent protein (GFP) or IL-24 complementary DNA. The results indicated that UC-MSCs could selectively migrate to glioma cells in vitro and in vivo. Injection of IL-24-UC-MSCs significantly suppressed tumor growth of glioma xenografts. The restrictive efficacy of IL-24-UC-MSCs was associated with the inhibition of proliferation as well as the induction of apoptosis in tumor cells. These findings indicate that UC-MSC-based IL-24 gene therapy may be able to suppress the growth of glioma xenografts, thereby suggesting possible future therapeutic use in the treatment of gliomas. K E Y W O R D S gene therapy, glioma, Interleukin 24 (IL-24), umbilical cord-derived mesenchymal stromal/stem cells (UC-MSCs)

No abstract

Though treatment techniques and strategies for colon cancer (CC) enhanced, the 5-year survival rate has not been significantly improved. Succinylation and long noncoding RNAs (lncRNAs) are uncertain for the prognostic value in the CC patients. We applied to analyze and obtain succinylation-related lncRNA by coexpression in CC. A novel succinylation-related lncRNA model was constructed by univariate and lasso regression analysis and established principal component analysis (PCA), functional enrichment annotation, tumor immune environment, drug sensitivity and nomogram to verify the model, respectively. Six succinylation-related lncRNA in CC were finally confirmed and distinguish the survival status in our model which was statistically significant differ in training set, testing set, and entire set. The prognosis value with this model associated with age, gender, M0 stage, N2 stage, T3+T4 stage and Stage III+IV. The high-risk group showed a higher mutation rate than the low-risk group. We constructed a model predict overall survival for 1-, 3-, and 5-year with AUCs of 0.694, 0.729, and 0.802. Cisplatin and Temozolomide compounds possess sensitivity in the high-risk group. Our study provided novel insights into the value of the succinylation related lncRNA signature as a predictor of prognosis, which possess high clinical application value in the future.